| BPH | Benign prostatic hyperplasia |
| CLIA | Clinical laboratory improvement amendments |
| CPT | Current procedural terminology |
| DRE | Digital rectal exam |
| HEOR | Health economic outcomes research |
| HLPC | High likelihood of prostate cancer |
| HIPAA | Health Insurance Portability and Accountability Act |
| IARC | International Agency for Research on Cancer |
| IHC | Immunohistochemistry |
| IRB | Institutional Review Board |
| LLPC | Low likelihood of prostate cancer |
| mpMRI | Multiparametric magnetic resonance imaging |
| MRI | Magnetic resonance imaging |
| PCa | Prostate cancer |
| PI-RADS | Prostate imaging reporting and data system |
| PLA | Proprietary laboratory analysis |
| PSA | Prostate-specific antigen |
| PSE | EpiSwitch® prostate cancer detection |
| SHAP | Shapley additive explanations |
| TRUS | Transrectal ultrasound |
| TAT | Turnaround time |
| WIRB | Western Institutional Review Board |
| XGBoost | Extreme gradient boosting |